Seres Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Seres Therapeutics, Inc. (Nasdaq: MCRB) on January 5, 2023, reporting events that occurred on January 4, 2023. The filing addresses corporate governance changes regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on director appointments and compensation arrangements.
Material Changes
On January 4, 2023, the Board of Directors increased its authorized size to ten directors and appointed Claire Fraser, Ph.D., as a Class II director. Dr. Fraser was also appointed to serve on the Audit Committee.
Compensation and Governance Details
- Annual Retainer: $45,000 for board service.
- Audit Committee Retainer: $10,000 annually.
- Equity Award: Initial option to purchase 48,000 shares of common stock.
- Exercise Price: $5.47 per share (closing price on the grant date).
- Vesting Schedule: Equal installments over four years or immediately upon a change in control.
Investor Verification Checklist
- Verify the total number of authorized directors on the Board is now ten.
- Confirm Dr. Fraser's independence status and qualifications for the Audit Committee.
- Review the impact of the new equity grant on total share count and dilution.
- Check for any related party transactions involving Dr. Fraser not disclosed in this filing.